NEJS · [臨床藥學] SAVOR-TIMI 53研究初期分析顯示,Saxagliptin並未顯著改善心血管預後(SAVOR-TIMI 53: Saxagliptin Failed to Improve CV Outcomes)...
確定! 回上一頁